Key questions about the checkpoint blockade-are microRNAs an answer?

Key questions about the checkpoint blockade-are microRNAs an answer?

The introduction of immune-checkpoint blockade in the cancer therapy led to a paradigm change of the management of late stage cancers. There are already multiple FDA approved checkpoint inhibitors and many other agents are undergoing phase 2 and early phase 3 clinical trials. The therapeutic indicat...

Full description

Bibliographic Details
Main Authors: Mihnea Dragomir, Baoqing Chen, Xiao Fu, George A. Calin
Format: Article
Language:English
Published: China Anti-Cancer Association 2018-06-01
Series:Cancer Biology & Medicine
Subjects:
MicroRNA
PD-1
PD-L1
CTLA-4
checkpoint inhibitors
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/1138

Similar Items

Similar Items